Integrated Biopharma (INBP) Stock Price
Integrated Biopharma Price
Revenue at Integrated Biopharma has contracted by 0.3% per year over the past 19 years to 54.35 M USD. For Integrated Biopharma, the net margin of 1.5% is down versus 12.6% a few years ago. The stock trades about 7% above its 52-week low.
Integrated Biopharma stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Integrated Biopharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Integrated Biopharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Integrated Biopharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Integrated Biopharma Price |
|---|---|
| 8/4/2026 | 0.16 USD |
| 8/3/2026 | 0.16 USD |
| 7/31/2026 | 0.16 USD |
| 7/30/2026 | 0.16 USD |
| 7/29/2026 | 0.16 USD |
| 7/27/2026 | 0.16 USD |
| 7/23/2026 | 0.16 USD |
| 7/22/2026 | 0.16 USD |
| 7/21/2026 | 0.16 USD |
| 7/20/2026 | 0.16 USD |
| 7/17/2026 | 0.16 USD |
| 7/16/2026 | 0.17 USD |
| 7/15/2026 | 0.16 USD |
| 7/14/2026 | 0.16 USD |
| 7/13/2026 | 0.16 USD |
| 7/10/2026 | 0.16 USD |
| 7/9/2026 | 0.16 USD |
| 7/8/2026 | 0.16 USD |
| 7/7/2026 | 0.17 USD |
| 7/6/2026 | 0.15 USD |
| 7/2/2026 | 0.18 USD |
| 7/1/2026 | 0.18 USD |
| 6/30/2026 | 0.18 USD |
| 6/29/2026 | 0.18 USD |
| 6/26/2026 | 0.18 USD |
| 6/25/2026 | 0.18 USD |
| 6/24/2026 | 0.17 USD |
| 6/23/2026 | 0.18 USD |
| 6/22/2026 | 0.18 USD |
| 6/18/2026 | 0.19 USD |
| 6/17/2026 | 0.19 USD |
| 6/16/2026 | 0.19 USD |
| 6/15/2026 | 0.19 USD |
| 6/12/2026 | 0.18 USD |
| 6/11/2026 | 0.18 USD |
| 6/10/2026 | 0.18 USD |
| 6/9/2026 | 0.18 USD |
| 6/8/2026 | 0.18 USD |
| 6/5/2026 | 0.18 USD |
| 6/4/2026 | 0.18 USD |
| 6/3/2026 | 0.19 USD |
| 6/2/2026 | 0.19 USD |
| 6/1/2026 | 0.19 USD |
| 5/29/2026 | 0.18 USD |
| 5/28/2026 | 0.18 USD |
| 5/27/2026 | 0.18 USD |
| 5/26/2026 | 0.18 USD |
| 5/22/2026 | 0.19 USD |
| 5/21/2026 | 0.19 USD |
| 5/20/2026 | 0.18 USD |
| 5/19/2026 | 0.22 USD |
| 5/18/2026 | 0.20 USD |
| 5/15/2026 | 0.21 USD |
| 5/14/2026 | 0.22 USD |
| 5/13/2026 | 0.21 USD |
| 5/12/2026 | 0.25 USD |
| 5/11/2026 | 0.25 USD |
| 5/8/2026 | 0.25 USD |
| 5/7/2026 | 0.25 USD |
| 5/6/2026 | 0.25 USD |
| 5/5/2026 | 0.25 USD |
| 5/4/2026 | 0.25 USD |
| 5/3/2026 | 0.25 USD |
| 4/15/2026 | 0.28 USD |
| 4/13/2026 | 0.28 USD |
| 4/10/2026 | 0.26 USD |
| 4/9/2026 | 0.27 USD |
| 4/7/2026 | 0.29 USD |
| 4/6/2026 | 0.29 USD |
| 4/1/2026 | 0.28 USD |
| 3/31/2026 | 0.27 USD |
| 3/27/2026 | 0.29 USD |
| 3/26/2026 | 0.28 USD |
| 3/23/2026 | 0.30 USD |
| 3/20/2026 | 0.29 USD |
| 3/19/2026 | 0.29 USD |
| 3/17/2026 | 0.28 USD |
| 3/16/2026 | 0.29 USD |
| 3/13/2026 | 0.30 USD |
| 3/12/2026 | 0.30 USD |
| 3/11/2026 | 0.30 USD |
| 3/2/2026 | 0.30 USD |
| 2/25/2026 | 0.29 USD |
| 2/24/2026 | 0.30 USD |
| 2/23/2026 | 0.30 USD |
| 2/19/2026 | 0.30 USD |
| 2/17/2026 | 0.30 USD |
| 2/16/2026 | 0.30 USD |
| 2/13/2026 | 0.30 USD |
| 2/11/2026 | 0.31 USD |
| 2/9/2026 | 0.32 USD |
| 2/6/2026 | 0.34 USD |
| 2/5/2026 | 0.33 USD |
| 2/2/2026 | 0.34 USD |
| 1/30/2026 | 0.33 USD |
| 1/29/2026 | 0.32 USD |
| 1/28/2026 | 0.34 USD |
| 1/27/2026 | 0.34 USD |
| 1/26/2026 | 0.34 USD |
| 1/23/2026 | 0.36 USD |
| 1/21/2026 | 0.36 USD |
| 1/20/2026 | 0.35 USD |
| 1/15/2026 | 0.37 USD |
| 1/13/2026 | 0.37 USD |
| 1/12/2026 | 0.35 USD |
| 1/9/2026 | 0.35 USD |
| 1/7/2026 | 0.34 USD |
| 1/6/2026 | 0.37 USD |
| 1/5/2026 | 0.38 USD |
| 1/2/2026 | 0.37 USD |
| 12/31/2025 | 0.36 USD |
| 12/30/2025 | 0.32 USD |
| 12/29/2025 | 0.34 USD |
| 12/26/2025 | 0.31 USD |
| 12/24/2025 | 0.31 USD |
| 12/23/2025 | 0.31 USD |
| 12/22/2025 | 0.31 USD |
| 12/19/2025 | 0.31 USD |
| 12/18/2025 | 0.31 USD |
| 12/16/2025 | 0.29 USD |
| 12/15/2025 | 0.31 USD |
| 12/12/2025 | 0.29 USD |
| 12/11/2025 | 0.31 USD |
| 12/9/2025 | 0.31 USD |
| 12/8/2025 | 0.31 USD |
| 12/7/2025 | 0.31 USD |
| 12/3/2025 | 0.31 USD |
| 12/2/2025 | 0.30 USD |
| 12/1/2025 | 0.31 USD |
| 11/27/2025 | 0.32 USD |
| 11/26/2025 | 0.32 USD |
| 11/24/2025 | 0.32 USD |
| 11/23/2025 | 0.32 USD |
| 11/21/2025 | 0.32 USD |
| 11/19/2025 | 0.31 USD |
| 11/18/2025 | 0.31 USD |
| 11/17/2025 | 0.30 USD |
| 11/16/2025 | 0.31 USD |
| 11/13/2025 | 0.27 USD |
| 11/12/2025 | 0.29 USD |
| 11/11/2025 | 0.29 USD |
| 11/10/2025 | 0.29 USD |
| 11/9/2025 | 0.31 USD |
| 11/7/2025 | 0.31 USD |
| 11/5/2025 | 0.29 USD |
| 11/4/2025 | 0.29 USD |
| 11/2/2025 | 0.30 USD |
| 10/30/2025 | 0.31 USD |
| 10/28/2025 | 0.30 USD |
| 10/27/2025 | 0.31 USD |
| 10/24/2025 | 0.31 USD |
| 10/22/2025 | 0.30 USD |
| 10/21/2025 | 0.30 USD |
| 10/15/2025 | 0.31 USD |
| 10/13/2025 | 0.31 USD |
| 10/12/2025 | 0.31 USD |
| 10/9/2025 | 0.31 USD |
| 10/6/2025 | 0.31 USD |
| 10/3/2025 | 0.28 USD |
| 10/2/2025 | 0.28 USD |
| 10/1/2025 | 0.29 USD |
| 9/30/2025 | 0.29 USD |
| 9/29/2025 | 0.29 USD |
| 9/25/2025 | 0.30 USD |
| 9/24/2025 | 0.31 USD |
| 9/23/2025 | 0.32 USD |
| 9/22/2025 | 0.33 USD |
| 9/18/2025 | 0.28 USD |
| 9/16/2025 | 0.29 USD |
| 9/15/2025 | 0.29 USD |
| 9/12/2025 | 0.29 USD |
| 9/11/2025 | 0.29 USD |
| 9/9/2025 | 0.28 USD |
| 9/8/2025 | 0.27 USD |
| 9/4/2025 | 0.27 USD |
| 9/3/2025 | 0.27 USD |
| 9/1/2025 | 0.27 USD |
| 8/29/2025 | 0.26 USD |
| 8/28/2025 | 0.27 USD |
| 8/25/2025 | 0.27 USD |
| 8/19/2025 | 0.26 USD |
| 8/18/2025 | 0.26 USD |
| 8/13/2025 | 0.27 USD |
| 8/12/2025 | 0.30 USD |
| 8/6/2025 | 0.28 USD |
Integrated Biopharma Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Integrated Biopharma Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.00 | 25.00 | 36.00 | 33.00 | 33.00 | 37.00 | 42.00 | 46.00 | 43.00 | 49.00 | 52.00 | 63.00 | 56.00 | 50.00 | 50.00 | 54.00 |
| -5.13 | -32.43 | 44.00 | -8.33 | – | 12.12 | 13.51 | 9.52 | -6.52 | 13.95 | 6.12 | 21.15 | -11.11 | -10.71 | – | 8.00 |
| 21.62 | 16.00 | 22.22 | 15.15 | 12.12 | 10.81 | 11.90 | 13.04 | 9.30 | 12.24 | 11.54 | 14.29 | 12.50 | 8.00 | 6.00 | 9.26 |
| 8.00 | 4.00 | 8.00 | 5.00 | 4.00 | 4.00 | 5.00 | 6.00 | 4.00 | 6.00 | 6.00 | 9.00 | 7.00 | 4.00 | 3.00 | 5.00 |
| – | – | – | 1.00 | 1.00 | – | 2.00 | 3.00 | 1.00 | 2.00 | 3.00 | 5.00 | 2.00 | – | – | 2.00 |
| – | – | – | 3.03 | 3.03 | – | 4.76 | 6.52 | 2.33 | 4.08 | 5.77 | 7.94 | 3.57 | – | – | 3.70 |
| – | – | – | – | – | – | – | 2.00 | – | 1.00 | 4.00 | 8.00 | 3.00 | – | – | – |
| – | – | – | – | – | – | – | – | – | – | 300.00 | 100.00 | -62.50 | – | – | – |
| 5.18 | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 | 5.18 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Integrated Biopharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Integrated Biopharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Integrated Biopharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Integrated Biopharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Integrated Biopharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Integrated Biopharma stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Integrated Biopharma Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Integrated Biopharma business model & stock analysis
Integrated Biopharma SWOT Analysis
Strengths
Integrated Biopharma Inc has a strong portfolio of biopharmaceutical products, including a diverse range of nutritional supplements and vitamins. These products are highly regarded for their quality and effectiveness.
The company has a well-established distribution network, allowing it to reach a wide customer base and expand its market share. This gives Integrated Biopharma Inc a competitive advantage over smaller companies in the industry.
Integrated Biopharma Inc is known for its research and development capabilities, constantly innovating and introducing new products to meet the evolving needs of consumers. This positions the company as a leader in the biopharmaceutical sector.
Weaknesses
One of the weaknesses of Integrated Biopharma Inc is its dependence on external suppliers for raw materials. Any disruption in the supply chain could impact the company's production capacity and product availability.
The company has limited market presence in certain geographical regions, limiting its access to potential customers. This poses a challenge for expanding its global reach and market penetration.
Integrated Biopharma Inc faces increasing competition from both established pharmaceutical companies and emerging biotech startups. This heightens the pressure to continuously innovate and differentiate its products to maintain a competitive edge.
Opportunities
The growing trend towards natural and organic products presents an opportunity for Integrated Biopharma Inc to further capitalize on its existing product line of nutritional supplements and vitamins.
Expanding into new markets, particularly in emerging economies, can open up new revenue streams for Integrated Biopharma Inc. These markets often have a rising middle class with increasing purchasing power and demand for healthcare products.
The advancements in biotechnology and personalized medicine offer potential for Integrated Biopharma Inc to develop innovative products that cater to specific patient needs. This can enhance the company's market position and profitability.
Threats
Changing government regulations and policies related to healthcare and pharmaceutical products pose a significant threat to Integrated Biopharma Inc. Compliance with these regulations can be costly and time-consuming.
The risk of intellectual property infringement and the emergence of generic products can erode Integrated Biopharma Inc's market share and profitability. Protecting its intellectual property rights through patents and trademarks is crucial.
Economic downturns and fluctuations in exchange rates can impact consumer spending patterns and affect the demand for healthcare products, potentially impacting Integrated Biopharma Inc's sales and revenue.
Integrated Biopharma Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Integrated Biopharma Segments
Integrated Biopharma Revenue by Segment (1/2)
3 Years
5 Years
10 Years
Max
Details
Integrated Biopharma Revenue by Segment (2/2)
3 Years
5 Years
Max
Details
Integrated Biopharma Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Integrated Biopharma Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Integrated Biopharma historical P/E ratio, EBIT multiple, and P/S ratio
Integrated Biopharma annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Integrated Biopharma shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Integrated Biopharma shareholder structure
| % | Name |
|---|---|
5.06976% | |
4.83138% | |
1.11395% | |
0.75151% | |
0.44490% | |
0.06417% |
Integrated Biopharma Executives and Management Board
7 members · avg. age 65 · 43 % women
Ms. Dina Masi (63)
Chief Financial Officer, Senior Vice President, Secretary
357,081.00 USD
Management
Ms. Christina Kay (54)
Co-Chief Executive Officer, Director · since 1994
Mrs. Riva Sheppard (57)
Co-Chief Executive Officer, Director · since 1991
Board of Directors
Mr. William Milmoe (76)
Director
Mr. Robert Canarick (74)
Independent Director
Mr. Eric Friedman (78)
Independent Director · since 1996
Mr. Damon DeSantis (56)
Director
Frequently asked questions about Integrated Biopharma
Integrated Biopharma Inc is a leading biopharmaceutical company that specializes in the development, manufacturing, and distribution of innovative healthcare products. The company operates through two main segments: Contract Manufacturing and Nutraceuticals. Integrated Biopharma Inc's business model revolves around providing contract manufacturing services to pharmaceutical and healthcare companies, offering a wide range of services including product development, formulation, packaging, and quality control. Additionally, the company also manufactures and markets a diverse portfolio of nutraceutical products that promote health and well-being. Integrated Biopharma Inc's commitment to quality, innovation, and customer satisfaction has made it a trusted partner in the biopharmaceutical industry.
Integrated Biopharma Inc is primarily active in the healthcare and pharmaceutical industries.
The main competitors of Integrated Biopharma Inc in the market include prominent companies such as Pfizer, Johnson & Johnson, Amgen, Roche Holding AG, and Novartis AG. These competitors are major players in the biopharmaceutical industry and compete with Integrated Biopharma Inc in areas including drug research and development, manufacturing, marketing, distribution, and sales.
Integrated Biopharma Inc is a reputable company with a rich history and background. Established in [year], Integrated Biopharma Inc has emerged as a leading player in the [industry] sector. The company specializes in [specific products or services] and has consistently delivered exceptional results. With a commitment to innovation and high-quality standards, Integrated Biopharma Inc has successfully developed and commercialized numerous breakthrough products. Over the years, the company has built strong partnerships, expanded its global presence, and garnered a solid reputation for reliability and customer satisfaction. Integrated Biopharma Inc continues to strive for excellence, driving growth and success in the market.
Integrated Biopharma Inc, a leading biotechnology company, has achieved several significant milestones. The company has successfully developed and commercialized a range of innovative pharmaceutical and dietary supplement products. Integrated Biopharma Inc has made notable strides in research and development, driving advancements in various therapeutic areas. With a focus on ensuring quality and safety, the company has obtained regulatory approvals for its products, further enhancing its market presence. Additionally, their commitment to continuous innovation and strategic partnerships has supported the company's growth and expanded its global reach. Integrated Biopharma Inc continues to make strides in the healthcare industry, establishing itself as a trusted and successful player.
Integrated Biopharma Inc is primarily present in countries and regions across the globe. With its global reach, the company has a strong presence in the United States, Europe, Asia, and other international markets. This diversified geographical presence allows Integrated Biopharma Inc to leverage various opportunities and cater to a wide customer base. By operating in multiple countries and regions, the company is able to tap into different market dynamics, expand its distribution network, and effectively serve its customers worldwide. Integrated Biopharma Inc's international presence is testament to its commitment to global growth and the delivery of its high-quality products and services.
Integrated Biopharma Inc represents values of innovation, scientific excellence, and commitment to improving human health. With a focus on the development, manufacturing, and marketing of high-quality nutraceutical and pharmaceutical products, the company prioritizes research-driven approaches to deliver effective solutions. Integrated Biopharma Inc embraces a corporate philosophy centered on enhancing wellness and longevity through its diverse portfolio of products. By constantly pushing the boundaries of biotechnology and prioritizing customer satisfaction, the company has established itself as a trusted name in the industry. Integrated Biopharma Inc's dedication to cutting-edge science and ethical business practices makes it a leader in the field of biopharmaceuticals.
Converted at the current exchange rate, the Integrated Biopharma share trades at 0.14 EUR (0.16 USD).
Integrated Biopharma Inc. is a diversified company specializing in the discovery, development, and marketing of innovative products in the fields of health, nutrition, and wellness. The company was founded in 1979 and is headquartered in New York, USA. The business model of Integrated Biopharma Inc. is based on various divisions, including the sale of raw materials, research and development, manufacturing of dietary supplements, and licensing of patents and technologies. The company offers a wide range of products, including natural raw materials such as herbs, extracts, and powders used in the manufacturing of dietary supplements and pharmaceutical products. Some of its well-known products include probiotics that improve gut health and digestion, as well as vitamins and minerals that help support a healthy lifestyle. Another division of Integrated Biopharma Inc. is research and development of new products. The company has its own research laboratory where innovative technologies and processes are developed to enhance the efficacy and safety of dietary supplements and drugs. The manufacturing of dietary supplements and pharmaceutical products is another important division of Integrated Biopharma Inc. The company operates its own production facilities and has extensive experience in producing products in compliance with the high-quality standards of the Food and Drug Administration (FDA). In addition to these divisions, Integrated Biopharma Inc. also offers licensing of patents and technologies. The company holds a variety of patents on innovative technologies in the fields of health, nutrition, and wellness and offers them for licensing. The business model of Integrated Biopharma Inc. is based on long-term relationships with customers and partners built on trust and quality. The company emphasizes collaboration with customers in product development and provides comprehensive customer service to ensure customer satisfaction. In summary, the business model of Integrated Biopharma Inc. is focused on the discovery, development, and marketing of innovative products in the fields of health, nutrition, and wellness. The company has divisions including raw materials, research and development, manufacturing of dietary supplements, and licensing of patents and technologies. Integrated Biopharma Inc. values quality and customer relationships and offers comprehensive customer service as well as long-term partnerships with customers and partners.
The revenue cannot currently be calculated for Integrated Biopharma.
The profit cannot currently be calculated for Integrated Biopharma.
The P/E ratio cannot be calculated for Integrated Biopharma at the moment.
The P/S cannot be calculated for Integrated Biopharma currently.
The Eulerpool Quality Score for Integrated Biopharma is 2/10.
The ISIN of Integrated Biopharma is US45811V1052. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Integrated Biopharma is 120093. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Integrated Biopharma is INBP. The ticker symbol is used to trade Integrated Biopharma shares on the stock exchange.
Integrated Biopharma paid dividends every year for the past 0 years.
Integrated Biopharma is assigned to the 'Non-cyclical consumption' sector.
The dividends of Integrated Biopharma are distributed in USD.
Integrated Biopharma stock
Integrated Biopharma Peer Group
Integrated Biopharma Ticker
Integrated Biopharma FIGI
All fundamentals and in-depth analysis of Integrated Biopharma
Our stock analysis for Integrated Biopharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Integrated Biopharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.